SAN FRANCISCO – The good news was that the 29th Annual J.P. Morgan Healthcare Conference kicked off Monday in San Francisco with 8,680 registered attendees, 1,400 more than last year – a sign that economic recovery is, if not here, then maybe not far away. Read More
SAN FRANCISCO – As attendees shuffled through crowded hallways of the Westin St. Francis Monday morning, more than one investor was overheard remarking on Celgene Corp.'s less than stellar kickoff of this year's J.P. Morgan Healthcare conference. Read More
New research this week identified a kinase that is involved in drug resistance of cancer cells in estrogen-driven breast cancer. The work also suggests that protein overexpression can be a useful method for identifying proteins that affect cancer cells, and provides new insights into the relationship between cancer and autophagy. Read More
Under a new partnership agreement between the two companies, GlaxoSmithKline plc will leverage Epizyme Inc.'s histone methyltransferase (HMT) platform to explore epigenetic targets for cancer therapy. Read More
Acadia Pharmaceuticals Inc., of San Diego, will receive $15 million in a private placement financing from New Enterprise Associates and Venrock. Read More
Cephalon, Inc., of Frazer, Pa., announced positive interim results from an ongoing multicenter Phase II trial of its "off-the-shelf" adult stem cell product Revascor for patients with congestive heart failure. Read More
Astellas Pharma Inc., of Tokyo, engaged Citigroup Global Markets Inc. to review its strategic altertnatives with respect to Prosidion Ltd., which it acquired with OSI Pharmaceuticals in June of 2010. Read More
